The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.
This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects.
Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Companies discussed in this report includes: AbbVie Inc., Addex Therapeutics Ltd, AGY Therapeutics, Inc., Amarantus Bioscience Holdings, Inc., AstraZeneca PLC, Avineuro Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cardax Pharmaceuticals, Inc., CoMentis, Inc., D-Pharm Ltd., Dart NeuroScience LLC, Eisai Co., Ltd., Eli Lilly and Company, Evotec AG, F. Hoffmann-La Roche Ltd., FORUM Pharmaceuticals Inc., H.
Lundbeck A/S, Heptares Therapeutics Ltd., Intra-Cellular Therapies, Inc., Iproteos S.L., Merck & Co., Inc., Mithridion, Inc., Mnemosyne Pharmaceuticals, Inc., Neuralstem, Inc., Novartis AG, Octapharma AG, Omeros Corporation, Pacific Northwest Biotechnology, LLC, Panacea Pharmaceuticals, Inc., Pfizer Inc., Pherin Pharmaceuticals, Inc., Sage Therapeutics, Saniona AB, Sanofi, Shire Plc, Siena Biotech S.p.A., SK Biopharmaceuticals Co., Ltd., Sunovion Pharmaceuticals Inc., Suven Life Sciences Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, Theratechnologies Inc., Upsher-Smith Laboratories, Inc., Vicore Pharma AB, Virogenomics, Inc.
Drug Profiles discussed in this report include: 2-PMPA, A-431404, ADX-92639, AN-761, AP-61, AQW-051, AUT-1, AUT-6, AUT-9, AVL-3288, AVN-211, BAN-2401, BCA-909, BI-409306, BMS-933043, BNC-375, C-21, CDD-0304, CDX-085, CSP-1103, DAOI-B, DP-NDD, Drug to Agonize Muscarinic M1/M4 Receptors for Psychosis and Cognitive Impairment, Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment, DSP-3748, E-1R, eltoprazine, encenicline hydrochloride, erteberel, EVT-501, FRM-0962, GTS-21, HTL-9936, idursulfase, immune globulin (human), IPR-001, IPR-088, IPR-19, irdabisant, ITI-214, ladostigil tartrate, levetiracetam, LUAF-64280, LY-3002813, NS-9283, NSI-189, PAN-811, Peptide T, PF-04958242, PH-15, PNU-120596, RO-4938581, roflumilast, RTL-551, SAGE-547, SAR-228810, SEN-15924, SKL-15508, Small Molecule to Agonize NMDA2B for CIAS, Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders, Small Molecule to Antagonize Histamine 3 Receptor for Cognition, Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders, Small Molecule to Inhibit Tyrosine Phosphatase for Cognition and Schizophrenia, Small Molecule to Target GPR151 for CNS Diseases, Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer, Small Molecules for Cognitive Impairment Associated with Schizophrenia, Small Molecules to Agonize 5-HT4 Receptors for Cognitive Impairment, Small Molecules to Agonize Beta-1 Adrenergic Receptor for Cognitive Impairment, Small Molecules to Agonize GABAA Receptor for Cognitive Impairment, Small Molecules to Agonize nAChR for Alzheimer''s Disease and Cognitive Impairment, Small Molecules to Antagonize 5-HT6 Receptors for Cognitive Impairment, Small Molecules to Inhibit Tyrosine Phosphatase for Cognition and Schizophrenia, Stem Cell Therapy for Cognitive Impairment, SUVN-501, SUVN-901, SUVN-976, SUVN-D-1108121, TAK-058, tesamorelin acetate, tropisetron hydrochloride, VU-0092273, xamoterol fumarate.
Complete report available @ http://www.rnrmarketresearch.com/cognitive-impairment-pipeline-review-h1-2015-market-report.html .
For more information:
News From
RnR Market Research Category: Industry Reports & Market Analysis Profile: RnRMarketResearch.com is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
